The discovery of migratory lesion in mandibular sclerosing osteomyelitis during biological inhibitors therapy: Two cases report and literature review.

IF 2.2 3区医学 Q2 Dentistry

Journal of Stomatology Oral and Maxillofacial Surgery Pub Date : 2024-11-14 DOI:10.1016/j.jormas.2024.102127

Weihua Han, Mu Wang, Ge Kong, Chen Li, Wen Zhang, Lian Zhou

{"title":"The discovery of migratory lesion in mandibular sclerosing osteomyelitis during biological inhibitors therapy: Two cases report and literature review.","authors":"Weihua Han, Mu Wang, Ge Kong, Chen Li, Wen Zhang, Lian Zhou","doi":"10.1016/j.jormas.2024.102127","DOIUrl":null,"url":null,"abstract":"Background: Diffuse sclerosing osteomyelitis (DSO) in mandible is a disease with unusual and undefined clinicoradiographic manifestations. Several medicines have been administrated for therapy, but the efficacy in bone remolding remains to be systematically evaluated.Observation: A 37-year-old male and a 28-year-old female were diagnosed DSO after revealing diffuse sclerosis and osteolytic changes in the mandible, and treated by Janus-activated kinase signal and IL-6 inhibitor, respectively. Their symptoms were well controlled and the inflammatory indicators were decreased. During the mandible remolding, the osteolytic destruction in one patient migrated from the left mandible to the right, while DSO lesion migrated from the left mandibular body to the ramus and condyle in the other.Conclusion: DSO presented as migratory lesions in mandible after biological inhibitors therapy, while the periosteal reaction wasn't conformed to the osteolytic focus. These findings suggest that periostitis may be the direct cause of DSO rather than the infectious triggers.","PeriodicalId":56038,"journal":{"name":"Journal of Stomatology Oral and Maxillofacial Surgery","volume":" ","pages":"102127"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatology Oral and Maxillofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jormas.2024.102127","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Dentistry","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diffuse sclerosing osteomyelitis (DSO) in mandible is a disease with unusual and undefined clinicoradiographic manifestations. Several medicines have been administrated for therapy, but the efficacy in bone remolding remains to be systematically evaluated.

Observation: A 37-year-old male and a 28-year-old female were diagnosed DSO after revealing diffuse sclerosis and osteolytic changes in the mandible, and treated by Janus-activated kinase signal and IL-6 inhibitor, respectively. Their symptoms were well controlled and the inflammatory indicators were decreased. During the mandible remolding, the osteolytic destruction in one patient migrated from the left mandible to the right, while DSO lesion migrated from the left mandibular body to the ramus and condyle in the other.

Conclusion: DSO presented as migratory lesions in mandible after biological inhibitors therapy, while the periosteal reaction wasn't conformed to the osteolytic focus. These findings suggest that periostitis may be the direct cause of DSO rather than the infectious triggers.

查看原文本刊更多论文

在生物抑制剂治疗期间发现下颌骨硬化性骨髓炎的移行性病变：两例报告和文献综述。

背景：下颌骨弥漫性硬化性骨髓炎（DSO）是一种临床放射学表现不常见、不明确的疾病。目前已有多种药物用于治疗，但对骨重塑的疗效仍有待系统评估：一名 37 岁的男性和一名 28 岁的女性在发现下颌骨弥漫性硬化和溶骨性改变后被诊断为 DSO，并分别接受了 Janusactivated 激酶信号和 IL-6 抑制剂的治疗。他们的症状得到了很好的控制，炎症指标也有所下降。在下颌骨重塑过程中，一名患者的溶骨性破坏从左侧下颌骨移向右侧，而另一名患者的DSO病变则从左侧下颌骨体移向颧骨和髁状突：结论：DSO在生物抑制剂治疗后表现为下颌骨的移行性病变，而骨膜反应与溶骨病灶并不一致。这些研究结果表明，骨膜炎可能是导致 DSO 的直接原因，而非感染诱因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Stomatology Oral and Maxillofacial Surgery Dentistry-Oral Surgery

CiteScore

2.20

自引率

9.10%

发文量

305

期刊介绍： J Stomatol Oral Maxillofac Surg publishes research papers and techniques - (guest) editorials, original articles, reviews, technical notes, case reports, images, letters to the editor, guidelines - dedicated to enhancing surgical expertise in all fields relevant to oral and maxillofacial surgery: from plastic and reconstructive surgery of the face, oral surgery and medicine, … to dentofacial and maxillofacial orthopedics. Original articles include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses. All manuscripts submitted to the journal are subjected to peer review by international experts, and must: Be written in excellent English, clear and easy to understand, precise and concise; Bring new, interesting, valid information - and improve clinical care or guide future research; Be solely the work of the author(s) stated; Not have been previously published elsewhere and not be under consideration by another journal; Be in accordance with the journal''s Guide for Authors'' instructions: manuscripts that fail to comply with these rules may be returned to the authors without being reviewed. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey Platforms.